International Collaborations

• European Mantle Cell Lymphoma (EMCL) Registry
• European Research Initiative on Chronic lymphocytic leukaemia (ERIC)
• Global NLPHL One Working Group (GLOW) Initiative
• Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
• T-Cell 2.0 – observational international registry of patients with newly diagnosed peripheral T-cell lymphoma

Current Projects

The Australasian Lymphoma Alliance (ALA)

The ALA has been in a long-term research partnership with the LaRDR. We value our collaboration with the ALA.

ERIC: European Research Initiative on Chronic lymphocytic leukaemia

ERIC is a current LaRDR partner looking to improve the outcomes of chronic lymphocytic leukaemia patients.

GLOW: Global nLPHL One Working GROUP

GLOW is a current LaRDR partner looking to collect data on nodular lymphocyte-predominant Hodgkin lymphoma.

HoLISTIC: Hodgkin Lymphoma International Study for Individual Care

HoLISTIC is a current LaRDR partner looking to optimise the clinical care of Hodgkin lymphoma patients.

T-cell Project 2.0

The T-cell Project 2.0 is a current LaRDR partner looking to improve understanding of Peripheral T-cell lymphoma.

2025

• Martynchyk A, et al. Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report. Intern Med J. 2025. https://doi.org/10.1111/imj.70037
• Wong EY, et al. Real-World Data on Lymphoma in Adolescents and Young Adults (AYA)—Report From the Lymphoma and Related Diseases Registry (LaRDR). eJHaem. 2025;6:e1096. https://doi.org/10.1002/jha2.1096
• Wang L & Chung E, et al. Definitions and use of tumour bulk in phase 3 lymphoma trials: a comprehensive literature review. Blood Advances. 2025. https://doi.org/10.1182/bloodadvances.2024015072

2024

• Baggio D, et al. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era. Internal Medicine Journal. 2024;54:1223-1227. http://doi.org/10.1111/imj.16445
• Binkley MS, et al. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma. Journal of Clinical Oncology. 2024;42:2271-2280. https://doi.org/10.1200/JCO.23.01655
• Barraclough A, et al. Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study. Haematologica. 2024;109(10):3338-3345. https://doi.org/10.3324/haematol.2023.284538
• Shaw B & Chung E, et al. Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project. European Journal of Haematology. 2024;1-8. https://doi.org/10.1002/jha2.870

2023

• Hapgood G, et al. The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood Advances. 2023;7(17):5047-5054. https://doi.org/10.1182/bloodadvances.2023010037.
• Goh Z, et al. Characteristics and Outcomes of Older Patients with Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study. Clinical Lymphoma, Myeloma and Leukemia. 2023;23(5):370-378. https://doi.org/10.1016/j.clml.2023.01.014

2022

• Nguyen J, et al. Clinical characteristics of Australian treatment-naïve patients with classical Hodgkin lymphoma from the lymphoma and related diseases registry. European Journal of Haematology. 2022;110(4):386-395. https://doi.org/10.1111/ejh.13915
• Baggio D, et al. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry. Leukemia & Lymphoma. 2022;64(3):621–627. https://doi.org/10.1080/10428194.2022.2157676
• Rodday AM, et al. The Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Development and Validation of a Clinical Prediction Model from the HoLISTIC Consortium. Journal of Clinical Oncology. 2022;41:2076-2086. https://doi.org/10.1200/JCO.22.02473
• Lymphoma and Related Diseases Registry Investigators. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry. BMC Medical Research Methodology. 2022;22:266. https://doi.org/10.1186/s12874-022-01728-0

2020

• Maqbool MG, et al. A practical guide to laboratory investigations at diagnosis and follow up in Waldenström Macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. Pathology. 2020;52(2):167-178. https://doi.org/10.1016/j.pathol.2019.11.002

2024

• Sungur S, et al. Body Mass Index and Clinical Associations in Australasian Lymphoma Patients: A Lymphoma and Related Diseases Registry Study. Poster presentation at: 66th ASH Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.
• Chung E, et al. Comparing outcomes using registry versus clinician definitions of bulky disease in lymphoma care: An Australasian Lymphoma Registry (LaRDR) study. Oral presentation at: ACTA 2024 Clinical Trials and Registries Symposium; December 2-4, 2024; Melbourne, Australia
• Yao Y, et al. Underweight Body Mass Index Is an Independent Risk Factor for Overall Survival in Diffuse Large B-Cell Lymphoma Treated with Rituximab, Prednisolone, Cyclophosphamide, Vincristine, and Doxorubicin: A Lymphoma and Related Diseases Registry Study. Poster presentation at: 66th ASH Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.
• Chung E, et al. Definition and Use of Bulky Disease in Lymphoma Care: A Study from the Australasian Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2024; October 27-30, 2024; Melbourne, Australia.
• Wang L, et al. The Definition and Use of Bulk Disease in Phase 3 Lymphoma Trials: A Comprehensive Literature Review. Poster presentation at: BLOOD 2024; October 27-30, 2024; Melbourne, Australia.
• Chung E, et al. Definition and Use of Bulky Disease in Lymphoma Care: A Study from the Australasian Lymphoma and Related Diseases Registry (LaRDR), Poster presentation at: EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.
• Wang L, et al. The Definition and Use of Bulk Disease in Phase 3 Lymphoma Trials: A Comprehensive Literature Review. Abstract Book at: EHA2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.

2023

• Al-Mashhadi AL, et al. Favorable Outcomes of Splenic Marginal Zone Lymphoma in an International Study of 934 Patients with Long Follow-up. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Evens AM, et al. Development and Validation of the Early-Stage Hodgkin Lymphoma International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Maurer MJ, et al. Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Poster presentation at: 65th ASH Annual Meeting and Exposition; December 9-12, 2023; San Diego, California.
• Shaw B, et al. Efficacy of polatuzumab combinations in relapsed/refractory diffuse large B cell lymphoma (RRDLBCL) trial-ineligible patients: a study from the Australian and New Zealand Lymphoma and Related Diseases Registry. Abstract Book at: BLOOD 2023; November 5-8, 2023; Melbourne, Australia.
• Wong E, et al. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Oral presentation at: Canberra Health Annual Research Meeting 2023; July 18 -21, 2023; Canberra, Australia.
• Manni M, et al. Mature T and NK cell lymphomas classified according to 2016 WHO classification. A report of 741 cases registered in the International Prospective T-cell Project 2.0. Poster presentation at: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi; June 13-17, 2023; Lugano, Switzerland.
• Shaw B, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory trial-ineligible large B cell lymphoma patients: An Australian Lymphoma Registry (LaRDR) study. Abstract Book at: 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi; June 13-17, 2023; Lugano, Switzerland.
• Shaw B, et al. Polatuzumab, bendamustine & rituximab (Pola-BR) efficacy in relapsed/refractory diffuse large B cell lymphoma (RRDLBCL) trial-ineligible patients: an Australian Lymphoma Registry (LaRDR) study. Abstract Book at: EHA2023 Hybrid Congress; June 8-15, 2023; Frankfurt, Germany.

2022

• Goh Z, et al. Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study. Poster presentation at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Los Angeles.
• Rodday AM, et al. Development and Validation of the Advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Oral presentation at: 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, Los Angeles.
• Bhopal S, et al. Defining the demographics, clinical presentation, and management of Australian patients with chronic lymphocytic leukaemia (CLL) on the Lymphoma and Related Diseases Registry (LaRDR), 2016 to 2021. Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Chai K, et al. Infection patterns and outcomes in patients with newly diagnosed CLL and NHL – Preliminary results from the Immunoglobulin use and Outcomes in CLL and NHL (ICAN) study. Oral presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Goh Z, et al. Characteristics and Outcomes of Elderly Patients with classicial Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Diseases Registry (LaRDR) Study. Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Ratnasingam S, et al. Patient characteristics and management of aggressive lymphoma in metropolitan and non-metropolitan centres in Australia from the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.
• Wong E, et al.. Real-world data on lymphoma in adolescents and young adults (AYA) – report from the Lymphoma and Related Diseases Registry (LaRDR). Oral presentation at: BLOOD 2022; September 11-14, 2022; Sydney, Australia.

2021

• Walker SK, et al. Real World Data on the Outcomes of Richter’s Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study. Poster presentation at: 63rd ASH Annual Meeting and Exposition; December 10-14, 2021; Atlanta, Georgia.
• Baggio D, et al. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian cohort: an analysis of the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D, et al. Ibrutinib in relapsed/refractory chronic lymphocytic leukaemia: interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D, et al. Ibrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL): interim analysis of outcomes on a Named Patient Program from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Nguyen J, et al. Clinical characteristics of Australian treatment-naïve classical Hodgkin Lymphoma (cHL) patients from the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Opat S, et al. Real world management of Lymphoma and Related diseases in Australia: The first five years of the Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Shipton M, et al. Patterns of treatment and outcomes in patients with large B-cell lymphoma: The Australian real-world experience. Oral presentation at: BLOOD 2021; September 20-23, 2021; Adelaide, Australia.
• Baggio D. Epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian context: an analysis of the Lymphoma and Related Diseases Registry. Oral presentation at: 13th Annual T-cell Lymphoma Forum; July 8-10, 2021.
• Federico M, et al. Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0. Hematological Oncology. 2021;39. https://doi.org/10.1002/hon.135_2880
• Federico M, et al. Subtypes of mature T and NK cell lymphomas according to 2016 WHO classification. Preliminary report of the International Prospective T-cell Project 2.0. E-poster gallery at: 16th International Conference on Malignant Lymphoma; June 18-22, 2021; Lugano, Switzerland.

2020

• Hawkes E. Achieving International Guidelines on PTCL: Are we closer to Global Standards of Care? The Australian TCL landscape. Oral presentation at: 12th Annual T-Cell Lymphoma Forum; February 3, 2020; San Diego, California. 

2019

• Barraclough A, et al. The ‘Real World’ Uptake and Prognostic Impact of GELF in Newly Diagnosed Follicular Lymphoma: An Australasian Alliance Initiative. Poster presentation at: 61st ASH Annual Meeting and Exposition; December 7-10, 2019; Orlando, Florida.
• Barraclough A, et al. Utility of GELF criteria in treatment decisions for follicular lymphoma (FL) treated in clinical practice. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• Clugston S, et al. Decision-making in CNS prophylaxis for DLBCL in a single institution. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• St George G, et al. The Lymphoma and Related Diseases Registry (LaRDR): A post-pilot update. Poster presentation at: BLOOD 2019; October 20-23, 2019; Perth, Australia.
• Yoo E, et al, Treatment patterns and outcomes of patients with follicular lymphoma (FL) at Sir Charles Gairdner Hospital (SCGH): An analysis of data from the Lymphoma and related diseases registry (LaRDR). Poster presentation at: BLOOD 2019; 2019 October 20-23; Perth, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data. Poster presentation at: ICML 2019; June 18-22, 2019; Lugano, Switzerland.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study In CArt-wheeL): A Global Patient-derived Data Registry mapping treatment and quality of life data. Poster presentation at: 24th Congress of EHA; June 13-16, 2019; Amsterdam, The Netherlands.

2018

• Dickinson M, et al. High rates of early treatment failure in diffuse large B-cell lymphoma: early results from the Lymphoma and Related Diseases Registry. Poster presentation at: BLOOD 2018; October 21-24, 2018; Brisbane, Australia.
• Xu K, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt-wheeL): Creating robust patient-reported data for observational research. Poster presentation at: BLOOD 2018; October 21-24, 2018; Brisbane, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s aldenström’s Macroglobulinemia Study Involving CArt-wheeL): A Global WM Registry for the Patient’s Voice A Global WM Registry for the Patient’s Voice. Poster presentation at: 10th International Workshop on Waldenström’s Macroglobulinemia; October 11-13, 2018; Manhattan, New York.
• Talaulikar D, et al. A national pathology review committee for the Lymphoma and Related Diseases Registry. Poster presentation at: RCPA Pathology Update 2018; March 2-4, 2018; Sydney, Australia.

2017

• Rowsell L, et al. The Lymphoma and Related Diseases Registry (LaRDR): Improving the quality of care for lymphoma patients. Poster presentation at: HAA 2017; October 29-November 1, 2017; Sydney, Australia.
• Tohidi-Esfahani I, et al. WhiMSICAL (Waldenström’s Macroglobulinemia Study Involving CArt -wheeL) update: Empowering patients internationally to contribute data for research. Poster presentation at: HAA 2017; October 29 –November 1, 2017; Sydney, Australia.

2016

• Morrison J, et al. Real world management of lymphoma: Development of the Australian and New Zealand Lymphoma and Related Diseases Registry (LaRDR). Poster presentation at: HAA 2016; November 13-16, 2016; Melbourne, Australia.